Introduction
The renin-angiotensin-aldosterone system (RAAS) appears to be fundamental to the left ventricular remodelling process that follows significant myocardial injury or inflammation. Key RAAS peptides, such as angiotensin II (Ang II) and aldosterone, are associated with pathological extracellular matrix deposition, myocyte hypertrophy and pro-apoptic effects, all key drivers of the ventricular remodelling process associated with progression of this disease. 1 The importance of the RAAS in heart failure progression is attested to by the therapeutic success of blockade of this system at key steps in its pathway, namely with angiotensin-converting enzyme (ACE) inhibitors, Ang II type 1 receptor blockers (ARB) and aldosterone receptor blockers. 2 Moreover, there is considerable pharmacological evidence to support blockade of the sympathetic nervous system (with beta-adrenoceptor blockers) as achieving its clinical benefits at least in part via blockade of the RAAS, specifically by inhibiting renin generation in the kidney. 3 With the advent of direct renin inhibitors (DRIs), much attention is now focussed on the importance of renin itself in the heart failure disease process as well as the therapeutic potential of its direct blockade in this setting.
Renin activation in heart failure
The RAAS is activated early in heart failure, although activation of the sympathetic nervous system appears to precede it. 4 Functional evidence, via measurement of plasma renin activity (PRA), suggests that renin (and prorenin) activation is a key component of overall RAAS activation. Renin activation in the kidney in this setting occurs in response to reduced urinary sodium excretion, decreased afferent glomerular arteriolar pressure and by preceding sympathetic nervous system activation. 5 Activation of RAAS components Ang II and aldosterone in heart failure appears to be of independent prognostic significance. 6 A key question therefore is whether renin activation itself is also independently prognostic or is merely associated with these downstream components of the RAAS. At present, it is very difficult to draw conclusions with regard to this issue as few studies have examined PRA or plasma renin concentration (PRC) and prognosis in multivariate analyses adjusting for other components of the RAAS. This is further complicated by concomitant chronic heart failure (CHF) therapies which may interfere with renin levels (see later).
One major issue that may impact on the question of renin's relevance in heart failure is the putative role of the (pro) renin receptor. 7 This receptor has been recently cloned and may represent an important non-RAAS pathway of reninmediated adverse actions on the cardiovascular system, including the heart. In particular, (pro) renin receptor activation of extracellular related kinase (1/2) 8 may be highly relevant to the cardiac remodelling process that follows myocardial injury. Extracellular related kinase itself is activated post-myocardial infarction and is considered a key survival pathway in hypertrophy 9 and heart failure, via activation of hypertrophic signals mediated upstream by glycoprotein receptor GP-130 as well as by induction of a foetal programme of gene expression. Other intracellular signalling cascades may also be activated by the putative (pro) renin receptor. Thus, there may be extra-RAAS pathways of cardiac damage initiated via activation of the (pro) renin receptor that are of relevance in the heart failure setting. In this way, (pro) renin receptor activation may be of particular relevance to the natural history of this condition, but that is currently pure speculation.
Impact of heart failure drug therapy on plasma renin levels
Both ACE-I and ARBs increase circulating PRC and PRA via reflex activation of the RAAS upstream. 10 In contrast, beta-blockers reduce synthesised renin and PRA via a β1-mediated inhibition of sympathetic activity at the juxtaglomerular apparatus in the kidney where renin is synthesised. 3 Thus, these commonly used heart failure agents have opposing actions on plasma renin.
Therapeutic potential of renin blockade in heart failure

Clinical utility
There are several lines of evidence to support direct renin inhibition as being potentially of clinical utility in CHF.
The first is that the RAAS has in general been an extremely successful therapeutic target in heart failure. Furthermore, there is considerable evidence that, at commonly used doses, blockade of the RAAS achieved by current therapies is incomplete, therefore further blockade of this system may be of therapeutic benefit. The concept of maximising RAAS inhibition is supported by data suggesting that higher doses of ACE-Is produce greater neurohormonal and haemodynamic benefits. 11 In addition, studies of ARB therapy added to background ACE inhibition, such as CHARM-Added 12 and Val-HeFT, 13 also support this concept, as does the addition of the aldosterone blocker, spironolactone, to background ACE-I in the RALES 14 study.
Next, the phenomenon of aldosterone escape is well described in heart failure, 15 having been observed in small mechanistic studies as well as in large-scale clinical trials such as Val-HeFT. This may occur in part because of the reflex activation of upstream renin by these downstream RAAS inhibitors as well as by non-ACE dependent mechanisms of generation of Ang II, e.g. chymase and cathepsin G. Therefore, blockade of the conversion of angiotensinogen to angiotensin I as mediated via renin by DRIs may be of considerable utility in maximising RAAS blockade, particularly in the setting of concomitant therapy with downstream RAAS inhibitory agents, as would be the case with most CHF patients.
Finally, DRIs may reduce agonist activation of the (pro) renin receptor and thus potentially RAASindependent adverse downstream effects on the myocardium. However, this concept is controversial. In particular, DRIs result in a reduction of PRA (i.e. the functional conversion of angiotensinogen to angiotensin I), but actually an increase in circulating PRC. It is the latter that is thought to interact with the renin receptor and therefore it is entirely possible that this receptor is activated rather than inhibited by DRIs. 16 Conversely, higher circulating renin levels may downregulate this receptor 17 and/or the DRIs themselves may interact with the receptor to inhibit its activation, i.e. act as functional receptor inhibitors. All of the above concepts are theoretical, contentious and not currently supported by any high level evidence.
Pre-clinical data
A number of early studies with low bioavailability DRIs has demonstrated beneficial effects of direct renin inhibition in models of systolic left ventricular dysfunction. 18 In particular, reduction in left ventricular end-diastolic pressure and systolic after-load has been observed with DRIs in a variety of animal species.
In addition, regression of left ventricular hypertrophy in spontaneously hypertensive rats has also been demonstrated. More recently, Pilz and colleagues tested a new orally bioavailable DRI (aliskiren) and found it to have similar antihypertrophic effects in double transgenic (renin, angiotensinogen overexpression) rats to the ARB, valsartan. 19
Clinical data
There have been very few studies of DRIs in patients with CHF. Early CHF studies of DRIs using intravenous remikiren found similar reductions in systemic vascular resistance and pulmonary capillary wedge pressure to intravenous enalaprilat, without further haemodynamic benefits when the two drugs were given together. 20 Similar findings have also been observed with intravenous enalkiren in such patients. 21 More recently, the orally bioavailable, long-acting DRI, aliskiren, has begun to be studied in CHF. Aliskiren may be a particularly useful agent in this setting as CHF patients often have co-morbid renal impairment and the drug is entirely metabolised via non-renal routes. 22 The first proof-of-concept study with aliskiren focussed on neurohormonal efficacy in 27 patients randomised to the ACE-I, ramipril, or the DRI. 23 Aliskiren 300 mg/day given for seven days to low left ventricular ejection fraction patients resulted in the expected reduction in PRA (compared with ramipril), greater reduction in Ang II and aldosterone, but a somewhat higher brain natriuretic peptide (BNP) response. Only the PRA and Ang II changes were statistically significant. This proofof-concept study established the therapeutic potential as well as relative safety of this agent in the systolic CHF setting.
The major study to evaluate the clinical utility of DRIs in CHF thus far has been ALOFT (ALiskiren Observation of heart Failure Treatment). 24 Three hundred and two patients with CHF (without left ventricular ejection fraction cut-off) were randomised to aliskiren (150 mg/day) or placebo. Patients had New York Heart Association Class II-IV heart failure, current or past history of hypertension, a plasma BNP level > 100 pg/ml and prior treatment with ACE-I (or ARB) and beta-blocker. Treatment duration was three months; 33% were taking an aldosterone antagonist, mean age was 68 years, most patients were New York Heart Association Class II and mean ejection fraction was 31%.
The primary efficacy end-point of the ALOFT study was change in plasma BNP levels. BNP is highly responsive to changes in intra-cardiac pressures and plasma levels are thus a marker of degree of ventricular dysfunction. Furthermore, plasma BNP levels are powerful prognostic predictors in established CHF 25 and have thus become useful surrogate markers of clinical efficacy in trials of CHF therapies. Plasma BNP levels were significantly reduced by aliskiren compared to placebo in ALOFT (figure 1). As expected, PRC was significantly increased and PRA significantly decreased by aliskiren in comparison to placebo. Urinary aldosterone levels were also significantly reduced by aliskiren versus placebo. A number of echocardiographic parameters of left ventricular remodelling were also significantly attenuated by aliskiren, most prominently mitral regurgitation area, peak early (E) transmitral flow velocity, E/A ratio, deceleration time and ratio of mitral velocity to early diastolic velocity of the mitral annulus.
These findings are supported by the ALiskiren Left ventricular Assessment of Hypertrophy (ALLAY) trial, 26 which observed beneficial effects of DRI on cardiac hypertrophy when compared to, as well as added to, the ARB, losartan.
The above findings, when taken together, suggest that DRIs may be of additional utility in the treatment of heart failure in as much as these parameters may represent surrogate markers of heart failure disease progression.
Potential adverse effects
Whilst DRI appears (based on the above considerations) to be of additional clinical utility to current RAAS blockers, there are a number of potential adverse effects that need to be considered with these agents in the overall management of the heart failure patient.
The major consideration is that CHF patients may already be receiving a number of RAAS blocking drugs (up to three differing classes) and therefore the potential side effect profile of further RAAS blockade needs to be considered. In particular, patients with CHF are particularly prone to hyperkalaemia due to reduced renal perfusion, co-morbid disease (e.g. diabetes mellitus) and concomitant therapies such as RAAS inhibitors and beta-blockers. Of note, in the ALOFT trial hyperkalaemia was somewhat greater in the aliskiren group compared to placebo although predefined cuts of potassium levels did not appear as a significantly higher percentage in aliskirentreated patients. Worsening renal function was also slightly, but not statistically, increased. Finally, symptomatic hypotension was also marginally increased with aliskiren compared to placebo. Therefore, there may be a biochemical and to a lesser extent clinical penalty for adding a DRI, but this does not appear to be excessive, paving the way for major outcome trials with this agent.
Future clinical trials with DRIs
On the basis of the above data, a large-scale clinical trial programme in systolic CHF with aliskiren has been announced by the drug's manufacturer, Novartis Pharmaceuticals. 27 This trial, ATMOS-PHERE (Aliskiren Trial to Minimise OutcomeS in Patients with HEart FailurE), will examine the potential clinical benefit of aliskiren additional to other RAAS blocking agents as well as comparing aliskiren head-to-head with ACE-I therapy. Precise details of the study have not as yet been announced. This study should answer key questions with regard to the clinical utility of DRIs in the CHF setting and, depending on the mechanistic sub-studies to be performed, may also investigate how these agents exert any observed benefits. Further to this, aliskiren will also be investigated in the ASTRONAUT (Aliskiren Trial on Acute Heart Failure Outcomes) which will evaluate whether early initiation of aliskiren therapy delays CV death and HF re-hospitalization within 6 months, posthospitalization for an episode of acute decompensated HF.
Conclusions
Given that CHF is associated with profound activation of the RAAS and renin appears to be fundamental to this activation, it seems logical that DRIs may play an important role in the amelioration of progression of this condition. Nevertheless, and as outlined in this review article, there are a number of challenges that remain before these agents become standard therapy. In particular, the question of whether DRIs offer anything more than merely maximising RAAS blockade remains unanswered. Furthermore, the role of the (pro) renin receptor and the net impact of direct renin blockade upon this receptor remain uncertain. The importance of renin and role of DRIs in heart failure with preserved ejection fraction have not even begun to be explored yet. Finally, the acceptability of the safety profile of DRIs in the CHF setting, additional to multiple other RAAS blockers (and beta-blockers which are indirect RAAS blockers), requires confirmation in a large scale trail. Nevertheless, despite the above unanswered questions, there seems to be sufficient positive pre-clinical and clinical data to venture into large-scale clinical trials, which will definitively address the above questions. Completion of such trials is therefore eagerly awaited.
